Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms

Neurobiol Aging. 2019 Jan:73:9-20. doi: 10.1016/j.neurobiolaging.2018.08.010. Epub 2018 Aug 30.

Abstract

We hypothesized that dopamine neuromodulation might affect cortical excitability in Parkinson's disease (PD) patients set in quiet wakefulness, as revealed by resting state eyes-closed electroencephalographic (rsEEG) rhythms at alpha frequencies (8-12 Hz). Clinical and rsEEG rhythms in PD with dementia (N = 35), PD with mild cognitive impairment (N = 50), PD with normal cognition (N = 35), and normal (N = 50) older adults were available from an international archive. Cortical rsEEG sources were estimated by exact low-resolution brain electromagnetic tomography. Compared with the normal older group, the PD groups showed reduced occipital alpha sources and increased widespread delta (<4 Hz) sources. Widespread frontal and temporal alpha sources exhibited an increase in PD with dementia compared with PD with mild cognitive impairment and PD with normal cognition groups, as function of dopamine depletion severity, typically greater in the former than the latter groups. A daily dose of levodopa induced a widespread reduction in cortical delta and alpha sources in a subgroup of 13 PD patients under standard chronic dopaminergic regimen. In PD patients in quiet wakefulness, alpha cortical source activations may reflect an excitatory effect of dopamine neuromodulation.

Keywords: Functional brain connectivity; Mild cognitive impairment due to Alzheimer's disease (ADMCI); Mild cognitive impairment due to Parkinson's disease (PDMCI); Resting state EEG rhythms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Cerebral Cortex / physiopathology*
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / physiopathology*
  • Electroencephalography / drug effects*
  • Female
  • Humans
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Rest / physiology*

Substances

  • Antiparkinson Agents
  • Levodopa